Using Model-based Meta-analysis to Inform Drug Development for Autoimmune Diseases

January 17, 2018 – MBMA helps sponsors design less costly and more precise trials with an eye toward achieving commercial success for both the drug and portfolio. Attend this webinar with Dr. Mark Lovern, Vice President at Certara Strategic Consulting, to learn how leveraging public data can provide value by abbreviating the “cash spiral” inherent to proprietary data.

Read More
Topics:
Learn More LinkedIn Twitter Facebook Email Subscribe to the Blog